Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : NKTR Drug delivery Company -- Ignore unavailable to you. Want to Upgrade?

To: Arthur Radley who wrote (278)	11/13/2007 4:11:40 PM
From: tuck	Read Replies (1) \| Respond to of 507

NKTR gets Exubera back and $135 million severance package from Pfizer. >>NEW YORK, and SAN CARLOS, Calif., Nov. 13 /PRNewswire-FirstCall/ -- Pfizer (NYSE: PFE - News) and Nektar Therapeutics (Nasdaq: NKTR - News) announced today that the two companies have resolved all outstanding contractual issues in connection with Exubera® and Nektar's innovative Next Generation Inhaled Insulin (NGI) product currently in Phase 1 clinical development. Under the terms of the agreement, Nektar will receive a one-time payment of $135 million from Pfizer in satisfaction of all remaining obligations under existing agreements relating to Exubera and NGI. In addition, in the event that a new partner is selected, Pfizer has agreed to transfer its remaining rights and all economic benefits for Exubera and NGI. This transfer of Pfizer's interests would include the transfer of the Exubera New Drug Application and Investigational New Drug Applications and all ex-U.S. regulatory filings and applications, continuation of ongoing Exubera clinical trials and certain supply chain transition activities. Jeffrey B. Kindler, Chairman and Chief Executive Officer of Pfizer and Howard W. Robin, President and Chief Executive Officer of Nektar issued the following joint statement today: "This agreement demonstrates the industry leadership of Pfizer and the company's desire to work with world-class biotechnology partners like Nektar. The agreement strengthens our relationship and demonstrates our ability to work together to craft a solution that allows Nektar the ability to pursue additional commercial opportunities for the Exubera and NGI inhaled insulin franchises. Further, we look forward to advancing our joint development of PEGylated human growth hormone therapy to treat short stature and growth problems."<< snip Nektar was near my put selling target price recently, but didn't quite get there. Now it likely won't. Cheers, Tuck